How much funding has Mediar Therapeutics raised?

Mediar Therapeutics has raised $282.0M in total funding, most recently a Series B round.

Who are Mediar Therapeutics's investors?

Mediar Therapeutics's investors include ICG Life Sciences, Amplitude Ventures, Intermediate Capital Group, Novartis Venture Fund, Sofinnova Partners, Atlas Venture.

When was Mediar Therapeutics founded?

Mediar Therapeutics was founded in 2019.

Where is Mediar Therapeutics headquartered?

Mediar Therapeutics is headquartered in Cambridge, Massachusetts, United States.

What industry is Mediar Therapeutics in?

Mediar Therapeutics operates in Biotech, Healthcare.

How many employees does Mediar Therapeutics have?

Mediar Therapeutics has 11-50 employees.

Mediar Therapeutics

New perspective. Novel targets. Clinical trials.

Cambridge, United States · Founded 2019 · $282.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: mediartx.com
Total Funding: $282.0M
Last Round: $76.0M Series BJun 2026
Rounds: 4

About

Mediar Therapeutics is pioneering first-in-class antibody treatments for fibrosis by targeting the myofibroblast — the cell responsible for scarring and disease progression. Founded from research at Mass General and Brigham and Women's Hospitals, the company focuses on IPF, systemic sclerosis, and kidney fibrosis.

Summary

Mediar Therapeutics is a Biotech company based in Cambridge, United States, founded in 2019. It has raised $282.0M in total across 4 rounds, most recently a $76.0M Series B round in Jun 2026. Investors include ICG Life Sciences, Amplitude Ventures and Intermediate Capital Group.